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Abstract 
The omics sciences of systems biology including genomics, transcriptomics, lipidomics, metabolomics, and pro-
teomics, aim at understanding the biological mechanisms that give rise to the phenotype of an organism by using 
high-throughput technologies with the promise of great medical advances. The importance of all these sciences 
is that all, with the exception of genomics are context dependent. Genome is constant in time and place in each 
cell of an organism, but the entire complement of messenger RNA molecules, proteins and metabolites in a cell, 
tissue, organ or organism varies with physiological, pathological or developmental conditions (Keusch 2006). 
The term “omics” represents the study of biological processes as systems. It deciphers the dynamic interactions 
between the numerous components of a biological system to analyse networks, pathways, and interactive rela-
tions that exist among them, such as genes, transcripts, proteins, metabolites, and cells. This new scientific vision 
has opened the way to new research strategies and experimental technologies that have transformed the study of 
virtually all life processes. Expansion of the “–ome” concept was incessant and has created a host of new terms, 
including bacteriome, cardiome, epigenome, erythrome, immunome, microbiome, neurome, connectome, 
osteome, physiome, proteinome, transportome, degradome, psychome, transcriptome, and many others. 
In the present review, these concepts are briefly introduced with a major focus towards proteomics. 
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1. Genomics, metabolomics, lipidomics, epigenomics 
 
Genomics is the study of the genomes of or-
ganisms. For several years genomics was at the 
forefront of omics sciences, we were in the 
“Genomic Era”. Because many diseases are in-
timately associated with genetic mutations, the 
idea that the solutions for human pathologies 
lie on genes has catalysed the interest of scien-
tists for years, making genome-based analysis 
methods a central approach in omics science 
and setting the scene for the completion of the 
Human Genome Project  (HGP), undoubtedly 
a major landmark event in the field of genomics 
after the discovery of the double-helical struc-
ture of DNA. Since the completion of the hu-
man genome project, our ability to explore ge-
nome function is increased in specificity. In 
fact, substantial changes have occurred in the 
study of genome owing to the introduction of 
several approaches to DNA sequencing and 
expression. The massive quantification of mes-
senger RNA (mRNA), genome copy number, 
and single nucleotide polymorphisms (SNPs) by 
microarray technology has enabled to assess the 
expression of tens of thousands of genes shed-
ding light on the mechanisms underlying hu-
man pathologies, providing the basis for strati-
fying patients and predicting outcomes in a va-
riety of diseases. Together with microarrays, re-
cent advances in DNA sequencing with the in-
troduction of next-generation sequencing 
(NGS) technologies have made possible un-
precedented extensive analyses of genome of 
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individuals. Presently, there are three main 
NGS systems: the Roche/454 FLX, the Illu-
mina/Solexa Genome Analyzer, and the Ap-
plied Biosystems SOLiDTM System. Each one, 
by a different approach, seeks to amplify single 
strands of a fragment library and perform se-
quencing reactions on the amplified strands. 
Together with these technologies, a new gen-
eration of single-molecule sequencing tech-
nologies is now emerging offering advantages 
over current sequencing methods including 
small amounts of starting material (theoretically 
only a single molecule may be required for se-
quencing), and low cost.  
An important consequence of this new emerg-
ing scenario was the creation of multi-
disciplinary teams and the formation of large-
scale collaborative networks to handle and inte-
grate these large amounts of data. The HGP 
was the first example of a large collaborative 
project; others include the Cancer Genome At-
las (TCGA) and the 1000 genome project. 
TCGA has achieved comprehensive sequenc-
ing, characterization, and analysis of the ge-
nomic changes of major types of human can-
cers providing also a platform for researchers to 
search, download, and analyse data sets gener-
ated by TCGA (http://cancergenome.nih.gov). 
The 1000 genome project aims to establish an 
extensive catalogue of human variations from 
25 populations (www.1000genomes.org). The 
project provides an international open access 
resource that serves as a basis for subsequent 
phenotype related studies 
(www.1000genomes.org). 
Endogenous metabolites can be seen as part of 
the downstream output of the genome, com-
plementary as ‘‘upstream’’ changes in genes 
(Spratlin, Serkova, and Eckhardt 2009), and 
their study together with exogenous metabolite 
is important to understand what happens in an 
organism. The term “metabolome” was intro-
duced in 1998 as the total metabolite content of 
a biological sample, an enormous complex and 
dynamic number of components that belong to 
a wide variety of compound classes, including 
nucleic acids, amino acids, sugars, and lipids. 
The term metabolomics was used for the first 
time in 2000 by Fien, to describe the discipline 
devot 
ed to the study of global metabolite profiles 
produced in biosynthetic and catabolic path-
ways from biological systems or originating 
from host-specific microbes and the intake of 
nutrients and pharmaceuticals, present in cells, 
tissues, and biofluids.  
Different techniques have been developed to 
investigate the metabolome, distinguishing the 
different metabolites on the basis of their 
chemical and physical properties (Cacciatore 
and Loda 2015). 
Most commonly used techniques for me-
tabolomics are nuclear magnetic resonance 
(NMR), gas chromatography coupled to mass 
spectrometer (GC–MS) and mass spectroscopy 
(MS). Recently published papers describe the 
application of metabolomics in the study of 
heart disease, cancer, and other human pa-
thologies. Another potential application of me-
tabolomics involves the definition of biochemi-
cal pathways that contribute to drug response. 
Pharmaco-metabolomic signatures have also 
been identified for several drugs to predict in-
dividual responses to broader medical, dietary, 
microbiological or physiological challenges.  
Data generated experimentally by metabolomics 
are available in metabolite databases such as the 
Human Metabolome Database (HMDB). 
HMDB (www.hmdb.ca), the equivalent of the 
Human Genome Project for metabolomics, is a 
resource dedicated to providing scientists with 
the most current and comprehensive coverage 
of the human metabolome. Created in 2004, it 
contains information on biological properties, 
ontology, spectra and physical properties of 
human metabolites as well as data regarding 
metabolite concentrations, disease associations 
and tissue locations. Started as an inventory of 
2500 small molecules, its content has increased 
to 15000 entries (Liesenfeld et al. 2013). 
Lipidomics, term emerged for the first time in 
2003, is a sub-discipline of metabolomics that 
aims to define all of the lipid molecular species 
in a cell, including the metabolizing enzymes 
and lipid transporters and understand how lip-
ids function in a biological system. In detail, 
lipidomics involves the identification of indi-
vidual cellular lipid species, including the type 
and number of individual atoms in each lipid 
species, and their stereoelectronic interactions 
with other lipids and proteins. Cells use 5% of 
their genes to synthesize their lipids that fulfil 
three main functions. Lipids not only forms the 
bilayer matrix, not only are used as energy stor-
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age, but can also act as second messengers and 
participate in signalling via specialized micro-
domains, lipid rafts, that have large amounts of 
lipids. The field of lipidomics is rapidly growing 
as demonstrated by the great utility of this ap-
proach to improve diagnostic–prognostic capa-
bilities for human disorders, and for the identi-
fication of new classes of lipids. Similarly to 
what happened for genome and metabolome, 
an attempt to characterize the mammalian lipi-
dome has started under the LIPID MAPS ini-
tiative (http://www.lipidmaps.org) in 2005. To 
accomplish this goal, a consortium of twelve 
independent laboratories from seven academic 
institutions and one company has been formed 
(Schmelzer et al. 2007; Fahy et al. 2009).  
Early separation and identification of lipids 
started with GC and HPLC, but other tech-
nologies coupled to chromatographic methods, 
such as MS, Matrix-assisted laser desorption-
ionization/time of flight (MALDI/TOF), 
NMR, and quadrupole–linear ion trap 
(QTRAP), provide now a powerful approach to 
the global analysis of complex lipid mixtures. 
Given the enormous complexity of cellular lipi-
domics, it has been estimated to encompass 
around 180 000 – 200 000 different lipid spe-
cies, high-throughput technologies are needed 
to approach the entire lipidome of cells. 
MALDI can also be used to reveal the distribu-
tion of lipids in tissues with the technique of 
imaging mass spectrometry (IMS) obtaining in-
formation relevant to the local distribution of 
lipids as they occur in tissues. 
The term ‘‘epigenetics’’ was originally coined by 
Conrad Waddington to describe heritable 
changes in a cellular phenotype that were inde-
pendent of alterations in the DNA sequence. 
DNA methylation, the transfer of a methyl 
moiety from S-adenosylmethionine (SAM) to 
the 5-position of cytosines in certain CpG di-
nucleotides, represents the most studied of epi-
genetic processes with a great impact on gene 
expression. Evidence is mounting for a direct 
link between DNA methylation and human dis-
eases. Chromatin changes are another central 
epigenetic process with a role in transcription, 
repair, replication, and condensation. Overall, 
there are now at least four different DNA 
modifications and 16 classes of histone modifi-
cations. Gene-specific techniques for determin-
ing DNA methylation include bisulfite sequenc-
ing, methylation-specific PCR (MSP) and quan-
titative MSP. The coupling of NGS platforms 
with established chromatin techniques such as 
chromatin immunoprecipitation (ChIP-Seq) 
represents the standard for identifying binding 
site locations for individual protein and histone 
modifications. 
 
 
2. The post-genome era: Proteomics 
 
The complete characterization of all proteins 
has been the goal of proteomics since its incep-
tion more than 20 years ago. Originally coined 
by Wilkins et al. in 1996, the term “proteome” 
refers to the entire PROTEin complement ex-
pressed by a genOME (Abdallah et al. 2012).  
Proteomics techniques offer several advantages 
over genome-based technologies, as they di-
rectly deal with the functional molecules rather 
than genetic code or mRNA abundance. Even 
though there is only one definitive genome in 
an organism, it codes for multiple proteomes 
since the accumulation of a protein changes in 
relation to the environment and is the result of 
a combination of transcription, translation, pro-
tein turnover, and posttranslational modifica-
tions. 
Proteins are the real-time executors of many 
biological functions and proteomics is the large-
scale study of proteins, including their struc-
tures, localizations, post-translational modifica-
tions (PTMs), and functions.  
Proteomics experiments also provide informa-
tion on protein interactions and complex for-
mation. For example, proteins interact with 
each other as part of large complexes that serve 
to execute most biological processes including 
signal transduction, transcription, and transla-
tion. A literature search at the start of 2013 
showed there were 38031 articles published on 
proteomics encompassing several research 
strategies; today, after four years, their number 
is more than doubled to a value of more than 
86000 articles. In both bacteria and eukaryotes, 
the cellular concentrations of proteins do not 
completely correlate with the abundances of 
their corresponding mRNAs. They often show 
a squared Pearson correlation coefficient of 
about 0.40, this means that about 40 % of the 
variation in protein concentration can be ex-
plained by knowing mRNA abundances. This 
25 2 57
OMICS Sciences: toward omics personalized medicine 
8 
individuals. Presently, there are three main 
NGS systems: the Roche/454 FLX, the Illu-
mina/Solexa Genome Analyzer, and the Ap-
plied Biosystems SOLiDTM System. Each one, 
by a different approach, seeks to amplify single 
strands of a fragment library and perform se-
quencing reactions on the amplified strands. 
Together with these technologies, a new gen-
eration of single-molecule sequencing tech-
nologies is now emerging offering advantages 
over current sequencing methods including 
small amounts of starting material (theoretically 
only a single molecule may be required for se-
quencing), and low cost.  
An important consequence of this new emerg-
ing scenario was the creation of multi-
disciplinary teams and the formation of large-
scale collaborative networks to handle and inte-
grate these large amounts of data. The HGP 
was the first example of a large collaborative 
project; others include the Cancer Genome At-
las (TCGA) and the 1000 genome project. 
TCGA has achieved comprehensive sequenc-
ing, characterization, and analysis of the ge-
nomic changes of major types of human can-
cers providing also a platform for researchers to 
search, download, and analyse data sets gener-
ated by TCGA (http://cancergenome.nih.gov). 
The 1000 genome project aims to establish an 
extensive catalogue of human variations from 
25 populations (www.1000genomes.org). The 
project provides an international open access 
resource that serves as a basis for subsequent 
phenotype related studies 
(www.1000genomes.org). 
Endogenous metabolites can be seen as part of 
the downstream output of the genome, com-
plementary as ‘‘upstream’’ changes in genes 
(Spratlin, Serkova, and Eckhardt 2009), and 
their study together with exogenous metabolite 
is important to understand what happens in an 
organism. The term “metabolome” was intro-
duced in 1998 as the total metabolite content of 
a biological sample, an enormous complex and 
dynamic number of components that belong to 
a wide variety of compound classes, including 
nucleic acids, amino acids, sugars, and lipids. 
The term metabolomics was used for the first 
time in 2000 by Fien, to describe the discipline 
devot 
ed to the study of global metabolite profiles 
produced in biosynthetic and catabolic path-
ways from biological systems or originating 
from host-specific microbes and the intake of 
nutrients and pharmaceuticals, present in cells, 
tissues, and biofluids.  
Different techniques have been developed to 
investigate the metabolome, distinguishing the 
different metabolites on the basis of their 
chemical and physical properties (Cacciatore 
and Loda 2015). 
Most commonly used techniques for me-
tabolomics are nuclear magnetic resonance 
(NMR), gas chromatography coupled to mass 
spectrometer (GC–MS) and mass spectroscopy 
(MS). Recently published papers describe the 
application of metabolomics in the study of 
heart disease, cancer, and other human pa-
thologies. Another potential application of me-
tabolomics involves the definition of biochemi-
cal pathways that contribute to drug response. 
Pharmaco-metabolomic signatures have also 
been identified for several drugs to predict in-
dividual responses to broader medical, dietary, 
microbiological or physiological challenges.  
Data generated experimentally by metabolomics 
are available in metabolite databases such as the 
Human Metabolome Database (HMDB). 
HMDB (www.hmdb.ca), the equivalent of the 
Human Genome Project for metabolomics, is a 
resource dedicated to providing scientists with 
the most current and comprehensive coverage 
of the human metabolome. Created in 2004, it 
contains information on biological properties, 
ontology, spectra and physical properties of 
human metabolites as well as data regarding 
metabolite concentrations, disease associations 
and tissue locations. Started as an inventory of 
2500 small molecules, its content has increased 
to 15000 entries (Liesenfeld et al. 2013). 
Lipidomics, term emerged for the first time in 
2003, is a sub-discipline of metabolomics that 
aims to define all of the lipid molecular species 
in a cell, including the metabolizing enzymes 
and lipid transporters and understand how lip-
ids function in a biological system. In detail, 
lipidomics involves the identification of indi-
vidual cellular lipid species, including the type 
and number of individual atoms in each lipid 
species, and their stereoelectronic interactions 
with other lipids and proteins. Cells use 5% of 
their genes to synthesize their lipids that fulfil 
three main functions. Lipids not only forms the 
bilayer matrix, not only are used as energy stor-
 Michele Maffia, Luana Conte, Marco Greco, Maria Chiara Maffia, Pasquale Simeone, Daniele Vergara  
9 
age, but can also act as second messengers and 
participate in signalling via specialized micro-
domains, lipid rafts, that have large amounts of 
lipids. The field of lipidomics is rapidly growing 
as demonstrated by the great utility of this ap-
proach to improve diagnostic–prognostic capa-
bilities for human disorders, and for the identi-
fication of new classes of lipids. Similarly to 
what happened for genome and metabolome, 
an attempt to characterize the mammalian lipi-
dome has started under the LIPID MAPS ini-
tiative (http://www.lipidmaps.org) in 2005. To 
accomplish this goal, a consortium of twelve 
independent laboratories from seven academic 
institutions and one company has been formed 
(Schmelzer et al. 2007; Fahy et al. 2009).  
Early separation and identification of lipids 
started with GC and HPLC, but other tech-
nologies coupled to chromatographic methods, 
such as MS, Matrix-assisted laser desorption-
ionization/time of flight (MALDI/TOF), 
NMR, and quadrupole–linear ion trap 
(QTRAP), provide now a powerful approach to 
the global analysis of complex lipid mixtures. 
Given the enormous complexity of cellular lipi-
domics, it has been estimated to encompass 
around 180 000 – 200 000 different lipid spe-
cies, high-throughput technologies are needed 
to approach the entire lipidome of cells. 
MALDI can also be used to reveal the distribu-
tion of lipids in tissues with the technique of 
imaging mass spectrometry (IMS) obtaining in-
formation relevant to the local distribution of 
lipids as they occur in tissues. 
The term ‘‘epigenetics’’ was originally coined by 
Conrad Waddington to describe heritable 
changes in a cellular phenotype that were inde-
pendent of alterations in the DNA sequence. 
DNA methylation, the transfer of a methyl 
moiety from S-adenosylmethionine (SAM) to 
the 5-position of cytosines in certain CpG di-
nucleotides, represents the most studied of epi-
genetic processes with a great impact on gene 
expression. Evidence is mounting for a direct 
link between DNA methylation and human dis-
eases. Chromatin changes are another central 
epigenetic process with a role in transcription, 
repair, replication, and condensation. Overall, 
there are now at least four different DNA 
modifications and 16 classes of histone modifi-
cations. Gene-specific techniques for determin-
ing DNA methylation include bisulfite sequenc-
ing, methylation-specific PCR (MSP) and quan-
titative MSP. The coupling of NGS platforms 
with established chromatin techniques such as 
chromatin immunoprecipitation (ChIP-Seq) 
represents the standard for identifying binding 
site locations for individual protein and histone 
modifications. 
 
 
2. The post-genome era: Proteomics 
 
The complete characterization of all proteins 
has been the goal of proteomics since its incep-
tion more than 20 years ago. Originally coined 
by Wilkins et al. in 1996, the term “proteome” 
refers to the entire PROTEin complement ex-
pressed by a genOME (Abdallah et al. 2012).  
Proteomics techniques offer several advantages 
over genome-based technologies, as they di-
rectly deal with the functional molecules rather 
than genetic code or mRNA abundance. Even 
though there is only one definitive genome in 
an organism, it codes for multiple proteomes 
since the accumulation of a protein changes in 
relation to the environment and is the result of 
a combination of transcription, translation, pro-
tein turnover, and posttranslational modifica-
tions. 
Proteins are the real-time executors of many 
biological functions and proteomics is the large-
scale study of proteins, including their struc-
tures, localizations, post-translational modifica-
tions (PTMs), and functions.  
Proteomics experiments also provide informa-
tion on protein interactions and complex for-
mation. For example, proteins interact with 
each other as part of large complexes that serve 
to execute most biological processes including 
signal transduction, transcription, and transla-
tion. A literature search at the start of 2013 
showed there were 38031 articles published on 
proteomics encompassing several research 
strategies; today, after four years, their number 
is more than doubled to a value of more than 
86000 articles. In both bacteria and eukaryotes, 
the cellular concentrations of proteins do not 
completely correlate with the abundances of 
their corresponding mRNAs. They often show 
a squared Pearson correlation coefficient of 
about 0.40, this means that about 40 % of the 
variation in protein concentration can be ex-
plained by knowing mRNA abundances. This 
OMICS Sciences: toward omics personalized medicine 
8 
individuals. Presently, there are three main 
NGS systems: the Roche/454 FLX, the Illu-
mina/Solexa Genome Analyzer, and the Ap-
plied Biosystems SOLiDTM System. Each one, 
by a different approach, seeks to amplify single 
strands of a fragment library and perform se-
quencing reactions on the amplified strands. 
Together with these technologies, a new gen-
eration of single-molecule sequencing tech-
nologies is now emerging offering advantages 
over current sequencing methods including 
small amounts of starting material (theoretically 
only a single molecule may be required for se-
quencing), and low cost.  
An important consequence of this new emerg-
ing scenario was the creation of multi-
disciplinary teams and the formation of large-
scale collaborative networks to handle and inte-
grate these large amounts of data. The HGP 
was the first example of a large collaborative 
project; others include the Cancer Genome At-
las (TCGA) and the 1000 genome project. 
TCGA has achieved comprehensive sequenc-
ing, characterization, and analysis of the ge-
nomic changes of major types of human can-
cers providing also a platform for researchers to 
search, download, and analyse data sets gener-
ated by TCGA (http://cancergenome.nih.gov). 
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their genes to synthesize their lipids that fulfil 
three main functions. Lipids not only forms the 
bilayer matrix, not only are used as energy stor-
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age, but can also act as second messengers and 
participate in signalling via specialized micro-
domains, lipid rafts, that have large amounts of 
lipids. The field of lipidomics is rapidly growing 
as demonstrated by the great utility of this ap-
proach to improve diagnostic–prognostic capa-
bilities for human disorders, and for the identi-
fication of new classes of lipids. Similarly to 
what happened for genome and metabolome, 
an attempt to characterize the mammalian lipi-
dome has started under the LIPID MAPS ini-
tiative (http://www.lipidmaps.org) in 2005. To 
accomplish this goal, a consortium of twelve 
independent laboratories from seven academic 
institutions and one company has been formed 
(Schmelzer et al. 2007; Fahy et al. 2009).  
Early separation and identification of lipids 
started with GC and HPLC, but other tech-
nologies coupled to chromatographic methods, 
such as MS, Matrix-assisted laser desorption-
ionization/time of flight (MALDI/TOF), 
NMR, and quadrupole–linear ion trap 
(QTRAP), provide now a powerful approach to 
the global analysis of complex lipid mixtures. 
Given the enormous complexity of cellular lipi-
domics, it has been estimated to encompass 
around 180 000 – 200 000 different lipid spe-
cies, high-throughput technologies are needed 
to approach the entire lipidome of cells. 
MALDI can also be used to reveal the distribu-
tion of lipids in tissues with the technique of 
imaging mass spectrometry (IMS) obtaining in-
formation relevant to the local distribution of 
lipids as they occur in tissues. 
The term ‘‘epigenetics’’ was originally coined by 
Conrad Waddington to describe heritable 
changes in a cellular phenotype that were inde-
pendent of alterations in the DNA sequence. 
DNA methylation, the transfer of a methyl 
moiety from S-adenosylmethionine (SAM) to 
the 5-position of cytosines in certain CpG di-
nucleotides, represents the most studied of epi-
genetic processes with a great impact on gene 
expression. Evidence is mounting for a direct 
link between DNA methylation and human dis-
eases. Chromatin changes are another central 
epigenetic process with a role in transcription, 
repair, replication, and condensation. Overall, 
there are now at least four different DNA 
modifications and 16 classes of histone modifi-
cations. Gene-specific techniques for determin-
ing DNA methylation include bisulfite sequenc-
ing, methylation-specific PCR (MSP) and quan-
titative MSP. The coupling of NGS platforms 
with established chromatin techniques such as 
chromatin immunoprecipitation (ChIP-Seq) 
represents the standard for identifying binding 
site locations for individual protein and histone 
modifications. 
 
 
2. The post-genome era: Proteomics 
 
The complete characterization of all proteins 
has been the goal of proteomics since its incep-
tion more than 20 years ago. Originally coined 
by Wilkins et al. in 1996, the term “proteome” 
refers to the entire PROTEin complement ex-
pressed by a genOME (Abdallah et al. 2012).  
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over genome-based technologies, as they di-
rectly deal with the functional molecules rather 
than genetic code or mRNA abundance. Even 
though there is only one definitive genome in 
an organism, it codes for multiple proteomes 
since the accumulation of a protein changes in 
relation to the environment and is the result of 
a combination of transcription, translation, pro-
tein turnover, and posttranslational modifica-
tions. 
Proteins are the real-time executors of many 
biological functions and proteomics is the large-
scale study of proteins, including their struc-
tures, localizations, post-translational modifica-
tions (PTMs), and functions.  
Proteomics experiments also provide informa-
tion on protein interactions and complex for-
mation. For example, proteins interact with 
each other as part of large complexes that serve 
to execute most biological processes including 
signal transduction, transcription, and transla-
tion. A literature search at the start of 2013 
showed there were 38031 articles published on 
proteomics encompassing several research 
strategies; today, after four years, their number 
is more than doubled to a value of more than 
86000 articles. In both bacteria and eukaryotes, 
the cellular concentrations of proteins do not 
completely correlate with the abundances of 
their corresponding mRNAs. They often show 
a squared Pearson correlation coefficient of 
about 0.40, this means that about 40 % of the 
variation in protein concentration can be ex-
plained by knowing mRNA abundances. This 
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demonstrates that proteomics represents a 
complementary to genomics approaches. 
The classic proteomics screening methodology 
combine two different approaches. The first 
one, called expression-based proteomics, has 
the aim to define the expression of all proteins 
present in biological samples. Traditionally, it is 
performed through the combination of several 
sequential steps including protein extraction, 
separation and identification. The general start-
ing point is the protein separation by an elec-
trophoresis system, one- or two-dimensional 
electrophoresis (1-DE or 2-DE), and the sub-
sequent identification of digested proteins by 
MS. Alternatively, proteins can also be digested 
using a specific protease and the resulting pep-
tides separated and analysed immediately by 
MS. Such approach, namely as shotgun, is con-
sidered the method of choice for the large-scale 
analysis of proteins. The strength of this ap-
proach is that it is unbiased; a drawback is that 
the outcome relies on analysis and interpreta-
tion of experimental data. By contrast, targeted 
proteomic using multiple-reaction monitoring 
mass spectrometry (MRM-MS) allows the selec-
tive detection and quantification of selected 
peptide ions. Such approach uses the capability 
of triple quadrupole mass spectrometers to act 
as ion filters. In a MRM-MS experiment, the 
precursor ion is isolated in the first quadrupole 
(Q1), fragmented within Q2 producing frag-
ment ions that are monitored using Q3. 
The second approach, functional proteomics, 
aims to define the biological role of proteins 
and to identify protein–protein interactions, or 
interactomes. Protein complexes can be puri-
fied in several ways, one very common ap-
proach is to use an affinity tag to the protein of 
interest and purify the interacting partners. 
Proteomics has emerged more than two dec-
ades ago as a post-genomic technology with the 
promise to unravel the cellular mechanisms of 
diseases and to develop reliable markers of di-
agnosis or treatment. However, such studies 
remain challenging owing to the high degree of 
complexity of cellular proteomes, in particular 
the serum/plasma proteome, and the low 
abundance of regulatory proteins hidden by 
abundant proteins. Due to the enormous varia-
tion in protein diversity, there is currently no 
single methodological platform that can be used 
for a full characterization of the proteome. 
2.1. Methods for protein separation 
 
The separation of all the proteins contained 
within cells, tissues, and biofluids remains a 
challenging analytical problem. Existing meth-
odologies are not adequate to completely isolate 
and resolve the large number of proteins pre-
sent at such different levels of concentration. 
Proteomic approaches can be classified as ei-
ther gel-based or gel-free methods that can be 
further subdivided in “label-free” or “label-
based”. 
 
2.1.1. Gel-based Proteomics: 2-DE 
The attempts to develop a 2-DE started in the 
late 60’, but it was O'Farrell in 1975 who opti-
mized a method on the basis that each electro-
phoresis separation must be done in independ-
ent parameter, to avoid protein being distrib-
uted across a diagonal rather than across the en-
tire surface of the gel (Magdeldin 2012). In the 
first dimension, protein molecules are resolved 
depending on their isoelectric point (pI); in the 
second dimension, protein separation is per-
formed based on molecular weight (Magdeldin 
et al. 2014). 
This technique has broadly affected life science 
research and successfully used applied to the 
study of biological or clinical samples for the 
purposes of identifying novel disease-specific 
protein biomarkers or gaining better under-
standings novel protein targets for therapeutic 
interventions and drug developments. During 
these years, several advances that have en-
hanced resolution, detection, quantitation, and 
reproducibility of the technique, increasing the 
robustness of the entire 2-DE workflow. One 
of the most notable improvements was the in-
troduction of immobilized pH gradient (IPG) 
gels that led to standardized procedures for 2-
DE permitting higher resolution and improved 
reproducibility for inter laboratory compari-
sons. More recently, the development of 2-D 
differential in-gel electrophoresis (DIGE) in 
1997 overcame problems of reproducibility and 
quantitation because allowed running test and 
control sample in the same gel. This method 
was designed in an attempt to increase sensitiv-
ity and reproducibility of 2-DE using multi-
plexed fluorescent dyes- labelled protein sam-
ples. 2D-DIGE is based mainly on running 
more than one sample (maximum 3) on a single 
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gel at once. Different fluorescent cyanine (Cy) 
dyes are used for labelling proteins from differ-
ent samples 
This technique enables protein detection at sub 
picomolar levels and relies on pre electropho-
retic labelling of samples with one of three 
spectrally resolvable fluorescent CyDyes (Cy2, 
Cy3, and Cy5) (Abdallah et al. 2012). Images are 
subsequently imported into dedicated 2-DE 
image analysis softwares. 
Although there has been a significant progress 
towards liquid chromatography and MS meth-
ods to separate and analyse proteins, 2-DE still 
remain a popular technique for conducting pro-
teomic studies. Proteins of interest are excised 
from the gel, proteolytically digested, and iden-
tified using MS (Figure 1). In a single run, up to 
1,000 – 2,000 protein species from one com-
plex sample can be separated. In specialised 
laboratories, using large-gel 2-DE method, the 
number of protein spots detected were drasti-
cally increased up to 10, 000. Subsequently, 2-
DE gel easily and efficiently couples with many 
other analysis and biochemical techniques; 
spots can be excised, proteins can be extracted 
and after a tryptic digestion analysed by mass 
spectrometry. 
Figure 1. A schematic workflow of two-dimensional gel elec-
trophoresis (2-DE). 2-D gel electrophoresis is an experimental 
technique that combines two separation methods. Biological 
samples are grown under different conditions and total proteins 
are extracted and subjected to isoelectric focusing (IEF) (first-
dimension electrophoresis), where proteins are separated ac-
cording to their isoelectric point (pI). After first dimension, 
IPG-strips are re-equilibrated to the second dimension buffer 
conditions, and transferred to the SDS-PAGE gels. Proteins on 
gels are visualized by MS-compatible stains, including 
Coomassie or silver staining. Software-based image analysis is 
then crucial for the biological interpretation of experiments. 
After statistical validation, differentially expressed spots from 2-
DE gels are excised, and a tryptic digestion is performed to 
generate tryptic peptide mixtures of the proteins that are ap-
plied to MALDI- or LC-MS/MS for identification of the ex-
cised proteins. The peptide data then are compared with the 
entire protein database (Swiss-Prot, NCBI). 
 
2.1.2 Gel free-based approaches 
Because of problems in quantitative reproduci-
bility and limitations on the ability to study cer-
tain classes of proteins, researchers have devel-
oped alternatives to 2-DE, for MS-based pro-
teomics techniques. 
High-resolution liquid chromatography (LC) 
separation coupled on line with a mass spec-
trometer is the central component of a gel free-
approach. Complex protein mixtures are di-
gested by trypsin into polypeptides, which are 
then separated by LC and analyzed by MS via 
an electro spray ionization (ESI) interface.  
In this approach is not the protein itself, which 
is separated and identified. Instead, proteins are 
cleaved into peptides using proteolytic enzymes 
and, subsequently, these peptides are separated 
and subjected to mass spectrometric analysis. 
This allows the determination of the protein 
content of the initial sample (Baggerman et al. 
2005). 
For this purpose, chromatographic separations 
are performed using flow rates in the range of 
low nanoliter per minute (nano-flow liquid 
chromatography or nanoLC). The relative 
quantification of peptides usually involves ei-
ther label-free or stable isotope labelling tech-
niques to identify differences in protein abun-
dances. The labelling methods can be classified 
into two main groups: chemical isotope tags 
and metabolic labelling. A variety of labelling 
approaches including, Proteolytic Labelling, 
Isotope-Coded Protein Labelling (ICPL), Iso-
tope-Coded Affinity Tags (ICATs), Isobaric 
Tags for Relative and Absolute Quantification 
(iTRAQ), TandemMass Tag (TMT), 14N/15N 
Labelling and Stable Isotope Labelling by 
Amino Acids in Cell Culture (SILAC) are valu-
able techniques in quantitative proteomic analy-
sis. The rationale behind each labelling strategy 
is to create a mass shift that distinguishes iden-
tical peptides that exhibit the same chroma-
tographic and ionisation properties, from dif-
ferent samples within a single MS analysis.  
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able techniques in quantitative proteomic analy-
sis. The rationale behind each labelling strategy 
is to create a mass shift that distinguishes iden-
tical peptides that exhibit the same chroma-
tographic and ionisation properties, from dif-
ferent samples within a single MS analysis.  
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Figure 2. A schematic workflow of gel free electrophoresis 
(Yang and Han 2016)  
 
3. Limitations of current proteomics approach 
 
In recent decades gel based proteomics tech-
niques became robust and reproducible, how-
ever two distinctive issues remains a challenge: 
the problems to detect low abundance and hy-
drophobic proteins. 
The question of under-representation of hy-
drophobic protein and in particular membrane 
proteins is well known and to explain this prob-
lem very different possible mechanisms have 
been proposed: (i) aggregation caused by the 
low solubility of these protein species in the 
aqueous media; (ii) protein loss over the se-
quential steps of the 2-DE processes; (iii) pre-
cipitation at the protein corresponding pI dur-
ing isoelectrofocusing phase; (iv) expression in 
low copy numbers; (v) difficulties to identify  
them by MS than hydrophilic proteins. Several 
fruitful strategies were considered to solve the 
problem. Usually, the best strategy in 2-DE ex-
periments is to solubilize proteins from the 
lipid layers by detergent and chaotropic salt. 
This can be performed by applying a solution 
of 2M thiourea, 8M urea, and 4% chaps. In the 
most recent years, other solutions were pro-
posed: use of different zwitterionic detergents, 
nonionic n-dodecyl β-D-maltoside and zwit-
terionic amidosulfobetaine ASB-14, and 1,2-
diheptanoyl-sn-glycero-3-phosphatdiyl choline 
(DHPC). Two organic solvents have been rec-
ommended for miscible extraction of red blood 
cells membrane proteins using methanol 
(MeOH), 2,2,2-tri- fluoroethanol (TFE) and 
urea. 
Despite the many solutions proposed in the re-
cent years the problems with hydrophobic pro-
teins, on 2D gels are widely unsolved. In fact, 
membrane protein solubility is low at their pI, 
and therefore membrane proteins tend to pre-
cipitate at their pI range. It is evident that the 
issue represents a built-in problem for all 2D 
electrophoresis systems IEF-based, for this rea-
son IEF-free separation systems represent a 
natural alternative in the analysis of membrane 
proteins. 
 
 
3.1 Protein abundance 
The large number of gene and gene splice-
variants that encode proteins, as well as the ex-
tensive post-translational modifications of eu-
karyotic proteins renders proteomic studies ex-
tremely difficult. The detection of specific, dis-
ease-related protein markers, notoriously diffi-
cult to identify, because expressed at low con-
centration, can be extremely challenging on a 
classical proteomic experiments where highly 
abundant proteins could obscure the rare ones. 
Consequently, there has been an extensive in-
vestment into developing techniques and 
methods capable of revealing the so named 
“hidden proteome”. This cannot be achieved 
by one single approach. In fact, several meth-
ods are used for the enrichment and visualiza-
tion of the low-abundance proteins and also for 
the depletion of the high-abundance proteins.  
It was demonstrated that the 10% most-
expressed gene products represented the 75% 
of the total protein content, and the 2/3 of less-
expressed only 10% of the protein content. In 
this situation is simple to argue that the signal 
of high-abundance proteins tends to hide the 
signal of rare species. 
Some of these technical difficulties can be by-
passed loading more sample, exploiting the 
great capacity of 2D gels, allowing many of low 
abundant proteins to be detected because above 
the detection limit. But high-loading approach 
is restricted by gel crowding and is related to 
the strong presence of normal and modified 
forms of high abundance protein species. This 
strategy gives gel with completely saturated 
zones with no increased performance in the 
visualization of low abundant species. Possible 
solutions proposed the use of giant gels with 
greater resolution and capacity. However, this 
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technology is inadequate and difficult to use 
due to the extreme fragility of the gels em-
ployed in the analysis. 
To address these issues, analytical chemists 
have attempted to develop pre-fractionation 
methods to separate large numbers of proteins. 
Fractionation based-methods that take advan-
tage of proteins function or structure are exten-
sively used, allowing the isolation of specific 
proteomes: glyco-proteome by lectin columns, 
phospho-proteome by anti-phospho-aminoacid 
antibodies or metal-chelating resins. However, 
these protocols do not resolve the challenge of 
signal suppression due to high-abundance spe-
cies present. Immunodepletion columns, con-
taining immobilized antibodies addressing the 
highest abundance proteins, were proposed as a 
possible solution. Though, these approaches 
cause the dilution of the initial sample, render-
ing it even more difficult to detect low-
abundance proteins. 
In this scenario, combinatorial hexapeptide 
ligand libraries have arisen as a powerful 
method for sample handling and are recently 
used to better elucidate and obtain extensive in-
formation on the protein composition of com-
plex samples like serum, bile fluid, human 
urine, platelet extracts, and red blood cell lysate. 
The ligand libraries, designed as batch of chro-
matographic beads, are synthesized by modified 
Merrifield approach described by Lam and col-
laborators. The library consists of millions of 
affinity baits (hexapeptides) so that each bead 
comprises multiple copies of the same bait. The 
beads represent the affinity solid phase of 
chromatographic column. This hexapeptide 
ligand library is assembled in order to be able to 
bind each single protein species present in a 
given biological extract. On the basis of the 
saturation-overloading chromatographic princi-
ple the loaded proteins are captured by their re-
spective specific ligand until saturation whereas 
the excess, unbound proteins are washed away. 
The proteins are captured from the peptide li-
brary by several and different combination of 
interacting forced: Van der Walls interactions, 
hydrogen bonding, structural docking, hydro-
phobic associations etc. Thus, high represented 
proteins species rapidly saturate their specific 
bead ligands while the excess of the same pro-
tein remains unbound. On the contrary, low-
abundance proteins were concentrated by their 
ligand up to saturation. Washing steps eliminate 
the protein excess not bound to the library and 
are removed from the chromatographic col-
umn. The protein species bound are eluted by a 
single appropriate elution buffer able of destroy 
proteins–hexapeptides interaction or by a se-
quence of desorbing agents, each of them ad-
dressing a selected type of binding. These frac-
tions can then be analyzed using well-known 
methods, such as SDS-PAGE, 2D electropho-
resis and MS. An application of hexapeptide li-
braries to cellular lysates is reported in Figure 2. 
Proteins obtained from the human T cell lym-
phoblast-like cell line Jurkat were used as start-
ing material to show the feasibility of this ap-
proach. 
 
Figure 3. Figure shows the 2-DE maps (pH 3-10) obtained 
from initial Jurkat cell line extract (top) as compared with those 
obtained from: (A) 2.5 mg/ml of proteins treated with library 
and eluted with RS solution (2 M thiourea, 7 M urea, 4% 
CHAPS); (B) 5 mg/ml of proteins treated with library and 
eluted with RS solution (2 M thiourea, 7 M urea, 4% CHAPS); 
(C) and (D) 14 mg/ml of proteins treated with library and 
eluted with RS solution (2 M thiourea, 7 M urea, 4% CHAPS) 
and RSA solution (2 M thiourea, 7 M urea, 4% CHAPS, acetic 
acid to pH 3.3), respectively. 
Jurkat cell line was maintained in RPMI-1640 medium contain-
ing 10% fetal bovine serum (FBS) and antibiotics. Cells were 
harvested by centrifugation followed by lysis via sonification in 
Tris buffer containing protease inhibitors. Varying amounts of 
cell lysate (2.5 mg/ml, 5 mg/ml, 14 mg/ml) were subjected to 
column chromatography over a solid-phase combinatorial 
ligand library (ProteoMiner, Biorad). Following washing, each 
individual column was subjected to two distinct elutions using a 
RS solution (2 M thiourea, 7 M urea, 4% CHAPS) and a RSA 
solution (2 M thiourea, 7 M urea, 4% CHAPS, acetic acid to pH 
3.3) respectively. RSA eluted sample was precipitated with 2D 
Clean-Up (GE Healthcare) and resuspended in RS. 
For 2-DE studies, 80 μg of proteins were dissolved in sample 
buffer and isoelectric focusing of protein samples was carried 
out by using commercial 13 cm IPG polyacrylamide strips (pH 
3 to 10 NL). Separation in the second dimension was carried 
out in 12% SDS-PAGE gels. Silver stained gels were scanned 
and analyzed by the software Image-Master 2-D Platinum. 
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4. Bioinformatics for high-throughput platforms 
 
Over the last decades, large-scale genome se-
quencing of model organisms and humans 
(Lander et al. 2001) has been a landmark 
achievement in biomedical sciences that was 
fueled by extraordinary advances in molecular 
biology and computer science. The broad appli-
cation of genomics and proteomics fields as 
well as the diffusion of high-throughput plat-
forms, have led to increasing the volume of 
available data requiring efficient algorithms 
along with new data management, new analysis 
and novel visualization techniques. This is in 
turn helped in redefining the synergy between 
biology, information sciences, mathematics, and 
computational techniques. This synergy is large-
ly used by researchers to analyze the infor-
mation on a large-scale, through the integration 
of computational algorithms, software tools and 
databases in an effort to address biological and 
medical questions. 
Luscombe et al. proposed a definition on bioin-
formatics as a union of biology and informatics: 
it involves the technology that uses computers 
for storage, retrieval, manipulation and distribu-
tion of information related to biological mac-
romolecules such as DNA, RNA, and proteins 
(Luscombe, Greenbaum, and Gerstein 2001).  
Initial research applications of bioinformatics 
were primarily focused on analysis of biological 
sequence data, genome content and rearrange-
ment, as well as for prediction of function and 
structure of macromolecules (Luscombe, 
Greenbaum, and Gerstein 2001). Over the last 
few decades, with the advent of high through-
put “omics”, it is now feasible to systematically 
profile a biological system at different levels of 
molecular and cellular organization, including 
its epigenome, transcriptome, metabolome, 
proteome, and interactome (Joyce and Palsson 
2006). Overtime, then, the broad nature and 
scale of these data types have spawned from 
conventional bioinformatics to specialized 
branch of bioinformatics such as comparative 
genomics (Miller et al. 2004), functional ge-
nomics (Vukmirovic and Tilghman 2000), net-
work biology (Barabási and Oltvai 2004) and 
computational proteomics (Colinge and Ben-
nett 2007). Moreover, with the subsequent real-
ization that the complete understanding of bi-
ology is obtained from multi level data integra-
tion, computational system biology has come 
into prominence.  
Mass spectrometry based proteomics has un-
dergone important advances in the scientific 
community, due to technological instrumenta-
tion and innovation in computational prote-
omics (Cox and Mann 2007) that is am inten-
sive discipline that requires extensive analytical 
and data-mining support and bioinformatics 
approaches.  
We can distinguish between qualitative prote-
omics and quantitative proteomics. In qualita-
tive proteomics, most of the bioinformatics ac-
tivities are focused on functional data mining of 
the dataset to extract the global biological 
theme underlying the proteome. The first step 
for functional interpretation of a protein list is 
to connect the protein identifier with its associ-
ated Gene Ontology Terms (GO_terms). 
Genes are then associated to hierarchically clus-
tered, functional terms that describe the “bio-
logical process”, “molecular function” or “cel-
lular component” (Schmidt 2014). Similarly to 
GO term enrichment analysis, proteins can also 
be analyzed for pathway abundance which 
might be more meaningful since allow the iden-
tification of functional biological processes as-
sociated to that protein (Schmidt 2014). Com-
prehensive pathway databases such as KEGG, 
include many interaction data coming from in-
tracellular reactions such as metabolism or sig-
naling pathways, genetic alterations or drug 
studies (Kanehisa et al. 2012). 
Genome-wide annotational datasets like GO, 
protein domain organization (PFAM, InterPro) 
(Mulder et al. 2007), pathways (KEGG) 
(Kanehisa et al. 2004) and disease mutations 
(OMIM) have been successfully used for func-
tional proteomics (Pasini et al. 2006). These an-
notations can be further used in conjuction 
with statistical tests to find over/under-
represented functional categories  (Adachi et al. 
2007). Additionally, integration with other high 
throughput “omics” datasets, such as microar-
ray, may provide valuable insights into proteo-
me expression and disease mechanisms 
(Graumann et al. 2008). 
In quantitative proteomics, we know that mass 
spectrometry provide quantitative data of pro-
teome changes in the cellular states. This in-
formation can be used on a binary level of pro-
tein changes, for instance normal vs cancer, 
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formation can be used on a binary level of pro-
tein changes, for instance normal vs cancer, 
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stimulated vs non-stimulated cells with growth 
factors as well as a step of cell cycle or differen-
tiation. There are a lot of methods and ap-
proaches for proteomics datasets across multi-
ple conditions or samples. However, in clinical 
applications of proteomics, biomarker discov-
ery can be done by comparison of proteome 
profiles of healthy and disease profiles, using 
genetic algorithms (Petricoin et al. 2002) and on 
building classification models for disease pre-
dictions. 
Microarrays have now permeated literally every 
field of biology and have found many applica-
tions in translational research. Large-scale mi-
croarray data are also becoming crucial for ex-
perimental biology along with computational 
algorithms, which find wider application in 
basic research, target discovery, drug discovery, 
biomarker identification and disease determina-
tion. Microarray Bioinformatics include, indeed, 
a range of inferential (Rhodes et al. 2002) and 
descriptive statistical methods. Reverse engi-
neering of gene networks using gene expression 
data based in Bayesian statistics (probabilistic 
models) (Friedman et al. 2000), Boolean and 
Relevance networks (Butte and Kohane 2000) 
and graph theoretic algorithms (Tringe, Wag-
ner, and Ruby 2004) are successfully applied to 
microarray data to uncover patterns in disease, 
especially in cancer (Lapointe et al. 2004).  
Bioinformatics approach for identification of 
cis-regulatory sequences has gained impetus in 
computational prediction of the gene regula-
tion, especially from recent discoveries in tran-
scriptional regulation by regulatory RNA 
(miRNA, siRNA, piRNA) and their targets 
(Bentwich 2008) as well as the current apprecia-
tion of the role of epigenetics. Bioinformatics 
applied to gene regulation is one of the most 
exciting areas of computational research. One 
of the principle means of coordinating tran-
scription spatially and temporally is through the 
presence of cis-regulatory elements. These 
short DNA sequence motifs, proximal to the 
transcriptional start site (TSS), are bound by 
transcription factors responsible for the re-
cruitment of the transcriptional initiation ma-
chinery and represent principle components 
that act in response to a particular cellular con-
text and extra-cellular inputs. Global elucidation 
of gene-specific cis-regulatory control will per-
mit the understanding of global transcriptional 
networks and facilitate our understanding of 
the properly functioning of biological system. 
In addition, de novo prediction of these bind-
ing sites has become an active area of research 
in the field of functional genomics. A complete 
understanding of this molecular algorithm give 
great impact on biological research, essential for 
gaining insights into development, cellular re-
sponses to environmental and genetic altera-
tions and the molecular basis of many diseases.  
The dynamic interplay between genes, proteins 
and metabolites leads to a complex biological 
network that include protein-protein interac-
tions, regulatory circuits linking transcription 
factors, cis-regulatory elements, signal transduc-
tion pathways and metabolic pathways. Net-
work bioinformatics is a fascinating areas of bi-
oinformatics and aims to study this complex 
biological circuit using mathematical modeling 
and simulation of pathways, graph-theory anal-
ysis of global network structure, application of 
engineering concept of network analysis as well 
as de novo design of networks. Protein-Protein 
interaction network, are typically visualized as 
“graph networks” where the nodes represent 
the protein, while an edge connecting two 
nodes. Protein-Protein interactions are often 
displayed as a networks illustrating the high de-
gree of connectivity and the presence of partic-
ular hub proteins. 
Genomics and bioinformatics are now poised 
to revolutionize our healthcare system by de-
veloping personalized and customized medi-
cine. The high speed genomic sequencing cou-
pled with sophisticated informatics technology 
will allow clinician to quickly sequence a pa-
tient’s genome and easily detect potential harm-
ful mutations and to engage in early diagnosis 
and effective treatment of diseases (Xiong 
2006).  
 
 
5. Clinical applications of proteomics 
 
With the advent of proteomics several large-
scale studies were launched to investigate the 
protein profile in different biological systems 
with the aim of discovering potential diagnostic 
and prognostic biomarkers. For example, in 
2000, the National Cancer Institute (NCI) es-
tablished an initiative titled the Early Detection 
Research Network (EDRN) which the objec-
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“graph networks” where the nodes represent 
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will allow clinician to quickly sequence a pa-
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4. Bioinformatics for high-throughput platforms 
 
Over the last decades, large-scale genome se-
quencing of model organisms and humans 
(Lander et al. 2001) has been a landmark 
achievement in biomedical sciences that was 
fueled by extraordinary advances in molecular 
biology and computer science. The broad appli-
cation of genomics and proteomics fields as 
well as the diffusion of high-throughput plat-
forms, have led to increasing the volume of 
available data requiring efficient algorithms 
along with new data management, new analysis 
and novel visualization techniques. This is in 
turn helped in redefining the synergy between 
biology, information sciences, mathematics, and 
computational techniques. This synergy is large-
ly used by researchers to analyze the infor-
mation on a large-scale, through the integration 
of computational algorithms, software tools and 
databases in an effort to address biological and 
medical questions. 
Luscombe et al. proposed a definition on bioin-
formatics as a union of biology and informatics: 
it involves the technology that uses computers 
for storage, retrieval, manipulation and distribu-
tion of information related to biological mac-
romolecules such as DNA, RNA, and proteins 
(Luscombe, Greenbaum, and Gerstein 2001).  
Initial research applications of bioinformatics 
were primarily focused on analysis of biological 
sequence data, genome content and rearrange-
ment, as well as for prediction of function and 
structure of macromolecules (Luscombe, 
Greenbaum, and Gerstein 2001). Over the last 
few decades, with the advent of high through-
put “omics”, it is now feasible to systematically 
profile a biological system at different levels of 
molecular and cellular organization, including 
its epigenome, transcriptome, metabolome, 
proteome, and interactome (Joyce and Palsson 
2006). Overtime, then, the broad nature and 
scale of these data types have spawned from 
conventional bioinformatics to specialized 
branch of bioinformatics such as comparative 
genomics (Miller et al. 2004), functional ge-
nomics (Vukmirovic and Tilghman 2000), net-
work biology (Barabási and Oltvai 2004) and 
computational proteomics (Colinge and Ben-
nett 2007). Moreover, with the subsequent real-
ization that the complete understanding of bi-
ology is obtained from multi level data integra-
tion, computational system biology has come 
into prominence.  
Mass spectrometry based proteomics has un-
dergone important advances in the scientific 
community, due to technological instrumenta-
tion and innovation in computational prote-
omics (Cox and Mann 2007) that is am inten-
sive discipline that requires extensive analytical 
and data-mining support and bioinformatics 
approaches.  
We can distinguish between qualitative prote-
omics and quantitative proteomics. In qualita-
tive proteomics, most of the bioinformatics ac-
tivities are focused on functional data mining of 
the dataset to extract the global biological 
theme underlying the proteome. The first step 
for functional interpretation of a protein list is 
to connect the protein identifier with its associ-
ated Gene Ontology Terms (GO_terms). 
Genes are then associated to hierarchically clus-
tered, functional terms that describe the “bio-
logical process”, “molecular function” or “cel-
lular component” (Schmidt 2014). Similarly to 
GO term enrichment analysis, proteins can also 
be analyzed for pathway abundance which 
might be more meaningful since allow the iden-
tification of functional biological processes as-
sociated to that protein (Schmidt 2014). Com-
prehensive pathway databases such as KEGG, 
include many interaction data coming from in-
tracellular reactions such as metabolism or sig-
naling pathways, genetic alterations or drug 
studies (Kanehisa et al. 2012). 
Genome-wide annotational datasets like GO, 
protein domain organization (PFAM, InterPro) 
(Mulder et al. 2007), pathways (KEGG) 
(Kanehisa et al. 2004) and disease mutations 
(OMIM) have been successfully used for func-
tional proteomics (Pasini et al. 2006). These an-
notations can be further used in conjuction 
with statistical tests to find over/under-
represented functional categories  (Adachi et al. 
2007). Additionally, integration with other high 
throughput “omics” datasets, such as microar-
ray, may provide valuable insights into proteo-
me expression and disease mechanisms 
(Graumann et al. 2008). 
In quantitative proteomics, we know that mass 
spectrometry provide quantitative data of pro-
teome changes in the cellular states. This in-
formation can be used on a binary level of pro-
tein changes, for instance normal vs cancer, 
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stimulated vs non-stimulated cells with growth 
factors as well as a step of cell cycle or differen-
tiation. There are a lot of methods and ap-
proaches for proteomics datasets across multi-
ple conditions or samples. However, in clinical 
applications of proteomics, biomarker discov-
ery can be done by comparison of proteome 
profiles of healthy and disease profiles, using 
genetic algorithms (Petricoin et al. 2002) and on 
building classification models for disease pre-
dictions. 
Microarrays have now permeated literally every 
field of biology and have found many applica-
tions in translational research. Large-scale mi-
croarray data are also becoming crucial for ex-
perimental biology along with computational 
algorithms, which find wider application in 
basic research, target discovery, drug discovery, 
biomarker identification and disease determina-
tion. Microarray Bioinformatics include, indeed, 
a range of inferential (Rhodes et al. 2002) and 
descriptive statistical methods. Reverse engi-
neering of gene networks using gene expression 
data based in Bayesian statistics (probabilistic 
models) (Friedman et al. 2000), Boolean and 
Relevance networks (Butte and Kohane 2000) 
and graph theoretic algorithms (Tringe, Wag-
ner, and Ruby 2004) are successfully applied to 
microarray data to uncover patterns in disease, 
especially in cancer (Lapointe et al. 2004).  
Bioinformatics approach for identification of 
cis-regulatory sequences has gained impetus in 
computational prediction of the gene regula-
tion, especially from recent discoveries in tran-
scriptional regulation by regulatory RNA 
(miRNA, siRNA, piRNA) and their targets 
(Bentwich 2008) as well as the current apprecia-
tion of the role of epigenetics. Bioinformatics 
applied to gene regulation is one of the most 
exciting areas of computational research. One 
of the principle means of coordinating tran-
scription spatially and temporally is through the 
presence of cis-regulatory elements. These 
short DNA sequence motifs, proximal to the 
transcriptional start site (TSS), are bound by 
transcription factors responsible for the re-
cruitment of the transcriptional initiation ma-
chinery and represent principle components 
that act in response to a particular cellular con-
text and extra-cellular inputs. Global elucidation 
of gene-specific cis-regulatory control will per-
mit the understanding of global transcriptional 
networks and facilitate our understanding of 
the properly functioning of biological system. 
In addition, de novo prediction of these bind-
ing sites has become an active area of research 
in the field of functional genomics. A complete 
understanding of this molecular algorithm give 
great impact on biological research, essential for 
gaining insights into development, cellular re-
sponses to environmental and genetic altera-
tions and the molecular basis of many diseases.  
The dynamic interplay between genes, proteins 
and metabolites leads to a complex biological 
network that include protein-protein interac-
tions, regulatory circuits linking transcription 
factors, cis-regulatory elements, signal transduc-
tion pathways and metabolic pathways. Net-
work bioinformatics is a fascinating areas of bi-
oinformatics and aims to study this complex 
biological circuit using mathematical modeling 
and simulation of pathways, graph-theory anal-
ysis of global network structure, application of 
engineering concept of network analysis as well 
as de novo design of networks. Protein-Protein 
interaction network, are typically visualized as 
“graph networks” where the nodes represent 
the protein, while an edge connecting two 
nodes. Protein-Protein interactions are often 
displayed as a networks illustrating the high de-
gree of connectivity and the presence of partic-
ular hub proteins. 
Genomics and bioinformatics are now poised 
to revolutionize our healthcare system by de-
veloping personalized and customized medi-
cine. The high speed genomic sequencing cou-
pled with sophisticated informatics technology 
will allow clinician to quickly sequence a pa-
tient’s genome and easily detect potential harm-
ful mutations and to engage in early diagnosis 
and effective treatment of diseases (Xiong 
2006).  
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With the advent of proteomics several large-
scale studies were launched to investigate the 
protein profile in different biological systems 
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tive to facilitate the development of biomarkers 
or technology that enable early detection of 
cancer. 
Specifically, this technology offers the possibil-
ity of identifying and quantifying proteins asso-
ciated with a particular disease by means of 
their altered levels of expression and/or PTMs 
between the control and disease states. This 
type of comparative analysis enables correla-
tions to be drawn between the range of pro-
teins, their variations and modifications pro-
duced by a cell, tissue and bio-fluids and the ini-
tiation, progression, therapeutic monitoring or 
remission of a disease state. Then, clinical pro-
teomics should be defined as the application of 
proteomic analysis with the aim of solving a 
specific clinical problem within the context of a 
clinical study. The potential applications of pro-
teomics goes from metabolic syndromes like 
inflammatory diseases or diabetes, to neurologi-
cal disorder, cancer, dietary interventions, to 
drug discovery or screening (Yang and Han 
2016). 
As clinical proteomics consists of a variety of 
experimental procedures, pre-analytical variabil-
ity, as well as analytical and post-analytical pro-
cedures can markedly affect a proteomic exper-
iment. Collection of appropriate clinical speci-
mens (e.g. urine, blood, tissue), duration of 
storage, number of freeze-thaw cycles, analysis 
of proteins and peptides of interest, data inter-
pretation, data validation of protein dataset in a 
specific clinical context should effectively be 
standardized to reduce bias. As a result, rec-
ommendations concerning minimal infor-
mation about a proteomic experiment (MIAPE) 
were released from the Human Proteome Or-
ganisation (HUPO). Reference materials are al-
so expected to support both qualitative and 
quantitative proteomic measurements. 
Despite substantial progress in the field, clinical 
proteomic approaches have not matured into 
routine diagnostic applications. As described 
above, proteomic analysis of blood and other 
body fluids and tissues is extremely difficult due 
to the complexity of samples and the dynamic 
range of concentrations of proteins in biologi-
cal fluids. Major challenges exist for plasma bi-
omarkers discovery, where the large dynamic 
concentration range of up to ten orders of 
magnitude for plasma proteins and the presence 
of very high abundance proteins such as serum 
albumin and immunoglobulins mask the lower 
abundance plasma biomarkers. Moreover, to 
validate biomarkers in a clinical setting it is re-
quired the analysis of hundreds (and perhaps 
more) of high-quality clinical samples. In fact, a 
huge amount of data and samples is necessary 
to ensure a bio-statistical significance. This large 
set of samples is in contrast with the time con-
suming and intensive proteomic approach that 
are distant from the routine of a clinical labora-
tory. 
Improvements in this field could lead the way 
to the use of “omic sciences” as a diagnostic 
tool for screening and early detection of many 
pathologies. But they also could represent 
prognostic and predictive tools, providing in-
formation about the outcome of diseases like 
breast cancers; triple negative tumours have a 
very worst prognosis than hormone responsive 
ones (Crutchfield et al. 2016).  
One of the major factors for successful prote-
omic analysis of clinical samples is the selection 
of an appropriate workflow. For instance, in 
studies that use biological fluids, samples 
should be pre-treated to remove high-
abundance proteins (running the risk also to 
eliminate proteins of interest because of pro-
tein-protein interactions) or concentrated to en-
rich the protein fraction (in the case of urine). 
In biomarkers discovery, caution must be exer-
cised in preserving samples for protein degrada-
tion, a problem that can lead to misinterpreta-
tion of data. 
Working with proximal fluids (synovial fluid, 
pleural fluid, peritoneal fluid, ascites) it should 
be necessary to eliminate the contamination of 
mucosa and salts before sample separation by 
2DE-MS, LC-MS), or capillary electrophoresis 
coupled to mass spectrometry (CE-MS). 
With regard to clinical proteomics, among the 
strategies that have the highest potential to re-
duce the gap between proteomics and its clini-
cal application there is the possibility to con-
duct a differential proteome analysis on tissue 
samples with the advantage to investigate the 
disease directly at the origin. Moreover, bi-
omarkers present in tissue are more concentrat-
ed than those released in the blood making this 
biological sample suitable for specific isolation 
or fractionation schemas. However, researchers 
who work with this type of sample are well-
aware that the great heterogeneity of human tis-
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sues represents a well-known limit in the inves-
tigation of biomarkers. Several approaches were 
developed to overcome this problem with the 
potential to be clinically useful. 2D electropho-
resis or SELDI (surface-enhanced laser desorp-
tion/ionization) have been coupled to laser 
capture microdissection (LCM), allowing the 
precise procurement of enriched cell popula-
tions from a heterogeneous tissue, or live cell 
culture, under direct microscopic visualization, 
or laser microdissection and pressure catapult-
ing techniques (LMPC). In this last procedure, 
after microdissection, the sample is directly cat-
apulted into an appropriate collection device. 
As the entire process works without any me-
chanical contact, it enables pure sample retriev-
al from morphologically defined origin without 
cross contamination. 
Among the strategies that have the highest po-
tential to reduce the gap between proteomics 
and its clinical application there is the possibil-
ity to conduct a differential proteome analysis 
directly on tissue samples with the advantage to 
investigate the disease directly at the origin. In 
these years, MALDI Imaging has emerged has 
another promising technique for the combined 
morphologic and molecular tissue analyses. In 
detail, MALDI Imaging allows to image/profile 
intact tissue sections placed onto a conductive 
glass side obtaining information about protein 
expression and localization. Because of its prac-
tical simplicity and ability to obtain reliable in-
formation from tissue section, MALDI imaging 
might have the potential to complement 
histopathologic evaluation for assisting in diag-
nostics, patient stratification, or predicting drug 
response. 
Together with technological challenges, other 
issues that could affect proteomic results 
should not be underestimated including har-
vesting, handling and storage of samples. Con-
sidering that the proteome is dynamic over time 
and expression of a myriad of factors, research-
ers should also consider the clinical history of 
the patient such as age, sex, and race. To mini-
mize these systemic problems is desirable to es-
tablish a specimen bank (biorepository). A 
sample, to become eligible for a biorepository, 
must be collected and analysed immediately be-
cause cells and proteins degradation and /or 
modification may affect the analysis. Moreover, 
sample should be subject to an accurate quality 
control and catalogued according to trusted, 
safe and standardized clinical data. 
Based on these observations we conclude that 
proteomics can be considered as a main strate-
gy for biomarker discovery. However, special 
attention has to be paid to reduce pre-analytical 
variables, analytical variability, and biological 
variation. This will require a close interdiscipli-
nary collaboration involving clinicians, statisti-
cians / bioinformatics, epidemiologists, chem-
ists, biochemists and biologists. 
 
 
6. Omics science: toward omic personalized medicine 
 
The availability of human genome sequence has 
transformed biomedical research over the past 
decade. The end of the 20th century was 
marked by the genomics revolution. However, 
over the past decades it has become clear that 
common diseases develop as a result of multi-
ple defects at different levels including proteins, 
lipids and metabolites, defects can that cannot 
be completely predicted by the simple analysis 
of genes. A systems-level approach, that inte-
grate the results of genomics with those ob-
tained by the analysis of metabolomes and pro-
teomes, has enabled researchers to utilize novel 
strategies to tackle unexplored research ques-
tions in human diseases. The ultimate goal is to 
evolve an integrated omics picture of the genes, 
transcripts, proteins, and metabolites to fully 
describe cellular functioning. At this regard in 
2014, a draft map of the human proteome was 
realised, using the high-resolution Fourier-
transform mass spectrometry (Kim MS et al. 
Nature 2014). In that review was reported a 
proteomic profiling of 30 histologically normal 
human samples, including 17 adult tissues, 7 fe-
tal tissues and 6 purified primary haematopoiet-
ic cells, that resulted in the identification of 
proteins encoded by 17,294 genes accounting 
for approximately 84% of the total annotated 
protein-coding genes in humans. The 
proteogenomic analysis revealed a number of 
novel protein-coding regions, which includes 
translated pseudogenes, non-coding RNAs and 
upstream open reading frames. This large hu-
man proteome catalogue (available as an inter-
active web-based resource at 
http://www.humanproteomemap.org) will 
complement available human genome and 
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transcriptome data to accelerate biomedical re-
search and in particular in the diagnosing and 
treating of human diseases 
The greatest benefits for patients are likely to 
be realized from the monitoring and manage-
ment of early stage disease rather than from 
treatment of late stage disease. In this field, a 
comprehensive integrative omic profiles was 
applied with success to perform an integrated 
Personal Omics Profiling (iPOP) on a single 
healthy individual. Authors of this study com-
bined genomic, transcriptomic, proteomic, 
metabolomic, and autoantibody profiles, in 
conjunction with routine laboratory testing, 
from a single individual over a 14 months peri-
od, generating an individual iPOP over the 
course of healthy states and two viral infections 
that occurred during the study interval. Periph-
eral blood mononuclear cells, plasma and serum 
were collected and results from whole-genome 
sequencing predicted an increased disease risks 
for various diseases, including hypertriglycer-
idemia, and type 2 diabetes (T2D). Markers as-
sociated with T2D became elevated during the 
course of study, in particular, following a res-
piratory infection. Moreover, data from omics 
experiments before and after viral infections al-
lowed for the creation of a dynamic picture of 
this process.  
Omics-based approaches will identify at risk 
groups supporting the implementation of risk-
stratified health screening. This may lead to sig-
nificant cost-savings at the societal level. 
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Summary box 
 
Given the complexity of cellular systems, sever-
al techniques have been developed over the 
years for the comprehensive analysis of molecu-
lar components. In particular, the advent of 
omic sciences has changed the way in which 
human diseases are studied making possible the 
simultaneous interrogation of thousands of mo-
lecular species at the system level. It was a 
technological revolution that modified the way 
in which experiments are designed, moving 
from mostly hypothesis- based approaches to 
studies that are largely hypothesis free. In this 
book chapter, we briefly discuss classical omics 
approaches including next-generation sequenc-
ing and metabolomics. More in detail, we have 
opted to focus our attention on proteomics, a 
complementary approach to genomics that over 
these years has led to important insights in the 
comprehension of cellular biological processes 
and human diseases. Current experimental limi-
tations including the enormous complexity and 
the dynamic nature of proteomes are also dis-
cussed.  
When integrated among them, omics approach-
es have the great potential to provide insight 
into the molecular alterations that drive disease 
pathogenesis. 
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